A new tool under development by University at Buffalo researchers could one day help clinicians better predict resistance to immunoglobulin therapy among children with Kawasaki disease in the United States. The new tool – described in a study published earlier this year in the Journal of Pediatric Pharmacology and Therapeutics – lays the groundwork for